Skip to main content
Erschienen in: Annals of Surgical Oncology 5/2017

20.12.2016 | Gynecologic Oncology

Treatment Preferences for Routine Lymphadenectomy Versus No Lymphadenectomy in Early-Stage Endometrial Cancer

verfasst von: Jung-Yun Lee, MD, PhD, Kyunghoon Kim, PhD, Yun Shin Lee, PhD, Hyo Young Kim, MS, Eun Ji Nam, MD, PhD, Sunghoon Kim, MD, PhD, Sang Wun Kim, MD, PhD, Jae Weon Kim, MD, PhD, Young Tae Kim, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Debate on the value of lymphadenectomy continues in endometrial cancer. The aim of this study was to investigate patient and clinician preferences for routine lymphadenectomy versus no lymphadenectomy in the surgical management of endometrial cancer.

Methods

A discrete choice experiment and trade-off question were designed and distributed to 103 endometrial cancer patients and 90 gynecologic oncologists. Participant preferences were quantified with regression analysis using scenarios based on three attributes: 5-year progression-free survival and the rates of acute and chronic complication. A trade-off technique varying the risk of recurrence for no lymphadenectomy was used to quantify any additional risk of recurrence that these participants would accept to receive no lymphadenectomy instead of routine lymphadenectomy.

Results

On the basis of discrete choice experiment, the recurrence rate and lymphedema risk had a statistically significant impact on respondents’ preference. The trade-off question showed that the median additional accepted risk of having no lymphadenectomy was 2.8% for gynecologic oncologists (0.5–14%) and 3.0% for patients (0.5–10%), but this difference was not significant (p = 0.620). Patients who were younger or had a higher education level or no history of delivery or shorter duration since diagnosis were prepared to accept higher additional risks of having no lymphadenectomy.

Conclusions

Our results show that the majority of endometrial cancer patients and clinicians will accept a small amount of recurrence risk to reduce the incidence of lymphedema. Regarding preference heterogeneity among patients, our results show that it is important for surgeons to take a patient-tailored approach when discussing surgical management.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Lim MC, Moon EK, Shin A, et al. Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999–2010. J Gynecol Oncol. 2013;24:298–302.CrossRefPubMedPubMedCentral Lim MC, Moon EK, Shin A, et al. Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999–2010. J Gynecol Oncol. 2013;24:298–302.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy versus no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100:1707–16. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy versus no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100:1707–16.
4.
Zurück zum Zitat Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373:125–36.CrossRefPubMed Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373:125–36.CrossRefPubMed
5.
Zurück zum Zitat Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2015;9:CD007585. Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2015;9:CD007585.
7.
Zurück zum Zitat Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27:16–41. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27:16–41.
9.
Zurück zum Zitat Lee JY, Kim K, Lee TS, et al. Controversies in the management of endometrial cancer: a survey of the Korean Gynecologic Oncology Group. J Gynecol Oncol. 2015;26:277–83.CrossRefPubMedPubMedCentral Lee JY, Kim K, Lee TS, et al. Controversies in the management of endometrial cancer: a survey of the Korean Gynecologic Oncology Group. J Gynecol Oncol. 2015;26:277–83.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Kennedy ED, Schmocker S, Victor C, et al. Do patients consider preoperative chemoradiation for primary rectal cancer worthwhile? Cancer. 2011;117:2853–62.CrossRefPubMed Kennedy ED, Schmocker S, Victor C, et al. Do patients consider preoperative chemoradiation for primary rectal cancer worthwhile? Cancer. 2011;117:2853–62.CrossRefPubMed
11.
Zurück zum Zitat Stalmeier PF, van Tol-Geerdink JJ, van Lin EN, et al. Doctors’ and patients’ preferences for participation and treatment in curative prostate cancer radiotherapy. J Clin Oncol. 2007;25:3096–100.CrossRefPubMed Stalmeier PF, van Tol-Geerdink JJ, van Lin EN, et al. Doctors’ and patients’ preferences for participation and treatment in curative prostate cancer radiotherapy. J Clin Oncol. 2007;25:3096–100.CrossRefPubMed
12.
Zurück zum Zitat van Tol-Geerdink JJ, Stalmeier PF, van Lin EN, et al. Do patients with localized prostate cancer treatment really want more aggressive treatment? J Clin Oncol. 2006;24:4581–6.CrossRefPubMed van Tol-Geerdink JJ, Stalmeier PF, van Lin EN, et al. Do patients with localized prostate cancer treatment really want more aggressive treatment? J Clin Oncol. 2006;24:4581–6.CrossRefPubMed
13.
Zurück zum Zitat Pieterse AH, Stiggelbout AM, Baas-Thijssen MC, van de Velde CJ, Marijnen CA. Benefit from preoperative radiotherapy in rectal cancer treatment: disease-free patients’ and oncologists’ preferences. Br J Cancer. 2007;97:717–24.CrossRefPubMedPubMedCentral Pieterse AH, Stiggelbout AM, Baas-Thijssen MC, van de Velde CJ, Marijnen CA. Benefit from preoperative radiotherapy in rectal cancer treatment: disease-free patients’ and oncologists’ preferences. Br J Cancer. 2007;97:717–24.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Wouters H, Maatman GA, Van Dijk L, et al. Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor–positive breast cancer. Ann Oncol. 2013;24:2324–9.CrossRefPubMed Wouters H, Maatman GA, Van Dijk L, et al. Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor–positive breast cancer. Ann Oncol. 2013;24:2324–9.CrossRefPubMed
15.
Zurück zum Zitat Blinman P, King M, Norman R, Viney R, Stockler MR. Preferences for cancer treatments: an overview of methods and applications in oncology. Ann Oncol. 2012;23:1104–10.CrossRefPubMed Blinman P, King M, Norman R, Viney R, Stockler MR. Preferences for cancer treatments: an overview of methods and applications in oncology. Ann Oncol. 2012;23:1104–10.CrossRefPubMed
16.
Zurück zum Zitat Stiggelbout AM, de Haes JC. Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol. 2001;19:220–30.CrossRefPubMed Stiggelbout AM, de Haes JC. Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol. 2001;19:220–30.CrossRefPubMed
17.
Zurück zum Zitat Lee JY, Cohn DE, Kim Y, et al. The cost-effectiveness of selective lymphadenectomy based on a preoperative prediction model in patients with endometrial cancer: insights from the US and Korean healthcare systems. Gynecol Oncol. 2014;135:518–24.CrossRefPubMed Lee JY, Cohn DE, Kim Y, et al. The cost-effectiveness of selective lymphadenectomy based on a preoperative prediction model in patients with endometrial cancer: insights from the US and Korean healthcare systems. Gynecol Oncol. 2014;135:518–24.CrossRefPubMed
18.
Zurück zum Zitat Cheville AL, Almoza M, Courmier JN, Basford JR. A prospective cohort study defining utilities using time trade-offs and the Euroqol-5D to assess the impact of cancer-related lymphedema. Cancer. 2010;116:3722–31.CrossRefPubMed Cheville AL, Almoza M, Courmier JN, Basford JR. A prospective cohort study defining utilities using time trade-offs and the Euroqol-5D to assess the impact of cancer-related lymphedema. Cancer. 2010;116:3722–31.CrossRefPubMed
19.
Zurück zum Zitat Lachance JA, Stukenborg GJ, Schneider BF, Rice LW, Jazaeri AA. A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma. Gynecol Oncol. 2008;108:77–83.CrossRefPubMed Lachance JA, Stukenborg GJ, Schneider BF, Rice LW, Jazaeri AA. A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma. Gynecol Oncol. 2008;108:77–83.CrossRefPubMed
20.
Zurück zum Zitat Dowdy SC, Borah BJ, Bakkum-Gamez JN, et al. Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. Gynecol Oncol. 2012;127:5–10.CrossRefPubMed Dowdy SC, Borah BJ, Bakkum-Gamez JN, et al. Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. Gynecol Oncol. 2012;127:5–10.CrossRefPubMed
21.
Zurück zum Zitat Papadia A, Bellati F, Ditto A, et al. Surgical treatment of recurrent endometrial cancer: time for a paradigm shift. Ann Surg Oncol. 2015;22:4204–10.CrossRefPubMed Papadia A, Bellati F, Ditto A, et al. Surgical treatment of recurrent endometrial cancer: time for a paradigm shift. Ann Surg Oncol. 2015;22:4204–10.CrossRefPubMed
22.
Zurück zum Zitat de Bekker-Grob EW, Niers EJ, van Lanschot JJ, Steyerberg EW, Wijnhoven BP. Patients’ preferences for surgical management of esophageal cancer: a discrete choice experiment. World J Surg. 2015;39:2492–9.CrossRefPubMedPubMedCentral de Bekker-Grob EW, Niers EJ, van Lanschot JJ, Steyerberg EW, Wijnhoven BP. Patients’ preferences for surgical management of esophageal cancer: a discrete choice experiment. World J Surg. 2015;39:2492–9.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Kunneman M, Pieterse AH, Stiggelbout AM, et al. Treatment preferences and involvement in treatment decision making of patients with endometrial cancer and clinicians. Br J Cancer. 2014;111:674–9.CrossRefPubMedPubMedCentral Kunneman M, Pieterse AH, Stiggelbout AM, et al. Treatment preferences and involvement in treatment decision making of patients with endometrial cancer and clinicians. Br J Cancer. 2014;111:674–9.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Kang S, Todo Y, Odagiri T, et al. A low-risk group for lymph node metastasis is accurately identified by Korean Gynecologic Oncology Group criteria in two Japanese cohorts with endometrial cancer. Gynecol Oncol. 2013;129:33–7.CrossRefPubMed Kang S, Todo Y, Odagiri T, et al. A low-risk group for lymph node metastasis is accurately identified by Korean Gynecologic Oncology Group criteria in two Japanese cohorts with endometrial cancer. Gynecol Oncol. 2013;129:33–7.CrossRefPubMed
25.
Zurück zum Zitat Barlin JN, Khoury-Collado F, Kim CH, et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol. 2012;125:531–5.CrossRefPubMed Barlin JN, Khoury-Collado F, Kim CH, et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol. 2012;125:531–5.CrossRefPubMed
26.
Zurück zum Zitat Koskas M, Fournier M, Vanderstraeten A, et al. Evaluation of models to predict lymph node metastasis in endometrial cancer: a multicentre study. Eur J Cancer. 2016;61:52–60.CrossRefPubMed Koskas M, Fournier M, Vanderstraeten A, et al. Evaluation of models to predict lymph node metastasis in endometrial cancer: a multicentre study. Eur J Cancer. 2016;61:52–60.CrossRefPubMed
27.
Zurück zum Zitat Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–20.CrossRefPubMed Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–20.CrossRefPubMed
Metadaten
Titel
Treatment Preferences for Routine Lymphadenectomy Versus No Lymphadenectomy in Early-Stage Endometrial Cancer
verfasst von
Jung-Yun Lee, MD, PhD
Kyunghoon Kim, PhD
Yun Shin Lee, PhD
Hyo Young Kim, MS
Eun Ji Nam, MD, PhD
Sunghoon Kim, MD, PhD
Sang Wun Kim, MD, PhD
Jae Weon Kim, MD, PhD
Young Tae Kim, MD, PhD
Publikationsdatum
20.12.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 5/2017
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5729-7

Weitere Artikel der Ausgabe 5/2017

Annals of Surgical Oncology 5/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.